CTA-MCI: Cognitive Control Training in Patients With Amnestic Mild Cognitive Impairment(CTA-MCI)

Launched by FIRST AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY · Apr 25, 2017

Keywords

ClinConnect Summary

Background:

Alzheimer's disease (AD) is a common dementia in elderly populations, and amnestic mild cognitive impairment (aMCI) refers to a transitional stage between normal aging and early dementia. Patients with aMCI are at higher risks of evolving toward AD. Although it has been widely recognized that early intervention of aMCI holds the potential to delay or even reverse the cognitive impairment, no treatment is available yet. Episodic memory dysfunction is the characteristic impairment in aMCI, cognitive control training significantly improved executive function in patients with aMCI ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Literate Chinese, aged 50 years and older
• • Complaint about memory loss and confirmed by an informant
• • Cognitive impairment in memory domain, adjusted for age and education
• • Normal or near-normal performance on general cognitive function and no or minimum impairment of daily life activities
• • Clinical dementia rating (CDR) =0.5, Mini-Mental State Examination (MMSE) score ≥ 20 (primary school) or ≥ 24 (junior school or above)
• • Failure to meet the criteria for dementia
• Exclusion Criteria:
• • history of clinically significant stroke
• • neurological diseases that may lead to neurological distortion, including schizophrenia, severe anxiety or depression, frontotemporal dementia，Huntington disease, brain tumor, parking disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal pressure hydrocephalus
• • systemic diseases that may lead to neurological distortion, including hypothyroidism, folic acid deficiency, vitamin B12 deficiency, severe anemia, specific infection such as HIV and syphilis
• • clinically significant gastrointestinal, renal, hepatic, respiratory, endocrine, or cardiovascular system disease;
• • cancer, alcoholism, drug addiction;
• • severe aphasia, physical disabilities, or any other factor that may preclude completion of neuropsychological testing;
• • use of medications that may affect cognitive functioning, including tranquilizers, anti-anxiolytics, hypnotics, nootropics, and cholinomimetic agents;
• • inability to undergo a brain MRI.